AquilaGen – Genetics for strategic drug development

Condimentum primis vitae sollicitudin tempus malesuada platea turpis. Announcement.

AquilaGen turns human genetic data into the actionable evidence that moves decisions

for biotech

for Pharma

and for investors

The genetic edge

Human genetic evidence is one of the most powerful tools available to de-risk drug targets, yet its potential remains largely untapped in early-stage R&D. It cuts through noise that animal models and observational data cannot, delivering causal evidence directly from human biology at the stage where it matters most.

0 x

Higher clinical success with genetic support

0 %

Of drugs fail due to insufficient target evidence from human causal data

0 k+

Human genetic datasets on clinical outcomes and molecular traits available for causal analysis

0 Weeks

From question to actionable insight

Your genetics team

AquilaGen is your dedicated genetics team. We embed our analytical rigour and commercial fluency to translate genetic findings into decisions that matter for your program: which target to progress.

MendelyticsTM: Rigour at speed

Through our MendelyticsTM, our team delivers deep genetic intelligence in weeks, without compromising the analytical rigor your decisions depend on. We maintain scientific integrity and transparency. Every output comes with full methodological transparency, so you understand not just what we found, but why you can trust it.

Services

AquilaGen translates human genetic data into actionable evidence — for biotechs building programs, pharma evaluating assets, and investors who need to de-risk before they commit. Our analytical approach is grounded in causal inference — the gold standard for understanding whether a drug target will actually work in humans. Our Mendelytics platform combines causal frameworks with AI and machine learning to curate, integrate, and interpret large-scale omics data into decision-ready evidence.

Clients

Intelligence built for the decision you’re about to make

Whether you’re a biotech building a program, a pharma team assessing an asset, or an investor deciding where to back a program — AquilaGen delivers the evidence layer specific to your question.

We produce the evidence your investors and partners will trust .

You’re building the case for your program — we make sure the genetic foundations hold. From target validation to biomarker strategy, we deliver the rigour that survives due diligence, strengthens your IND narrative, and gives your scientific story a causal backbone.

Independent genetic validation that survives.

The science in a deck is always compelling. We tell you whether the genetics agree. A rapid assessment of the causal evidence behind a target — benchmarked against the competitive landscape, so you know not just whether the biology holds, but whether it holds better than the alternatives.

Before you back the story, know if the biology holds.

Independent genetic validation that survives scrutiny, and strengthens the case your internal teams are already building.

Clients

Intelligence built for the decision you’re about to make

Whether you’re a biotech building a program, a pharma team assessing an asset, or an investor deciding where to back a program — AquilaGen delivers the evidence layer specific to your question.

We produce the evidence your investors and partners will trust .

Independent genetic validation that survives.

Before you back the story, know if the biology holds.

Independent genetic validation that survives scrutiny, and strengthens the case your internal teams are already building.

Clients

Intelligence built for the decision you’re about to make

Whether you’re a biotech building a program, a pharma team assessing an asset, or an investor deciding where to back a program — AquilaGen delivers the evidence layer specific to your question.